1547P Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
S. Kilickap1, F. Bugdaycı Bas¸al2, A. Demirkazik3, P. Gursoy4, U. Demirci5, M. Erman1, F. Yumuk6, F. Cay Senler3, B. Cakar7, I. Cicin8, A. Ozturk9, H.S. Coskun10, E. C¸ubukc¸u11, A. Is¸ıkdogan12, O.F. Olmez13, A.M. Tatlı14, M. Karaagac15, T. S¸akalar16, Y. Eralp17, T. Korkmaz18
1
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey,2Medical Oncology, Abdurrahman Yurtarslan Research and Training Hospital, Ankara, Turkey,3Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey,4Medical Oncology, Suat Seren Chest Disease Hospital, _Izmir, Turkey,5Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Training Hospital, Health Sciences University, Ankara, Turkey,6Medical Oncology, Marmara University School of Medicine, _Istanbul, Turkey,7Tulay Aktas Oncology Hospital, Ege University Medical School, Izmir, Turkey,8Medical Oncology, Trakya University Rekto¨rlu¨gu¨, Edirne, Turkey, 9
Medical Oncology, Sureyyapasa Chest Disease Hospital, _Istanbul, Turkey,10Medical Oncology, Akdeniz University Medical Oncology, Antalya, Turkey,11Department of Medical Oncology, Ali Osman So¨nmez Oncology Hospital, Bursa, Turkey,12Medical Oncology, Dicle University, Diyarbakır, Turkey,13Medical Oncology, Medipol Mega Hospitals Complex (University Hospital), Istanbul, Turkey,14Medical Oncology, Antalya Education and Training Hospital, Antalya, Turkey,15Medical Oncology, Konya Meram Faculty of Medicine, Konya, Turkey,16Medical Oncology, Erciyes University School of Medicine, Kayseri, Turkey,17Medical Oncology, Istanbul University, Institute of Oncology, Surgical Oncology Unit, Istanbul, Turkey,18Medical Oncology, Mehmetali Aydınlar Acıbadem University Faculty of Medicine, Istanbul, Turkey
Background:ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþ patients who have Ple-I/E.
Methods:In this multicenter study, patients with ALKþ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALKþ patients with NSCLC. Results:Of the patients, 198 (54.7%) were male. The median age at the time of diagno-sis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p¼ 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p¼ 0.541). The rate of smokers was 43.4% (n ¼ 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p¼ 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALKþ patients with Ple-I/E com-pared to those with non-metastatasis (respectively 18.2% vs 4.8%, p¼ 0.008; 19.1% vs 4.8%, p¼ 0.002; 20.6% vs 8.9%, p ¼ 0.003). The median PFS was longer in ALKþ patients who have Ple-I/E 18.7 vs 10.6 months, p¼ 0.017). The 1-, 2- and 3-year PFS
were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALKþ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p¼ 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement.
Conclusions:Brain, liver and bone metastases are lower in ALKþpatients with Ple-I/E. Presentation with Ple-I/E in patients with ALKþ NSCLC is associated with longer over-all and progression-free survival.
Legal entity responsible for the study:The authors. Funding:Has not received any funding.
Disclosure:All authors have declared no conflicts of interest.
1548P Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance S. Michels1 , B. Massuti Sureda2 , H-U. Schildhaus3 , J. Franklin4 , M. Sebastian5 , E. Felip6 , C. Grohe7 , D.F. Rodrıguez-Abreu8 , H. Bischoff9 , E. Carcereny Costa10 , J. Corral Jaime11 , A. Insa12 , M. Reck13 , M. Scheffler1 , N. Karachaliou14 , S. Merkelbach-Bruse15 , L. Nogova1 , R. Bu¨ttner15 , R. Rosell16 , J. Wolf1 1
Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany,
2
Department of Medical Oncology, Hospital General Universitario de Alicante, Alicante, Spain,3
Institute of Pathology, University Hospital of Essen, Essen, Germany,4
Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany,5
Department of Hematology/Medical Oncology, Universit€atsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, Germany,
6
Medical Oncology Service (Lung Cancer Unit), Vall d’Hebron University Hospital, Barcelona, Spain,7
Pneumology, Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, Germany,8
Servicio de Oncologıa Me´dica, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain,9
Oncology, Thoraxklinik Heidelberg, Heidelberg, Germany,10
Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain,11
Medical Oncology, Clınica Universitaria de Navarra, Madrid, Spain,12
Medical Oncology Department, Hospital Clınico Universitario de Valencia, Valencia, Spain,13
Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf, Germany,14
Oncology, Hospital Universitari Sagrat Cor -Group Quironsalud, Barcelona, Spain,15
Institute of Pathology, University Hospital Cologne, Cologne, Germany,16
Laboratory of Cellular and Molecular Biology, Institut for Healh Sciences Germans Trias i Pujol, Badalona, Spain
Background: ROS1 fusions are found in 1% of lung cancer patients. EUCROSS is the first prospective European trial to evaluate crizotinib in this patient subset. Here we
